Blockbuster metabolic exclusivity is decided in the courtroom rather than the clinic.
As the financial stakes for weight-loss blockbusters escalate, developers deploy aggressive regulatory litigation and cross-border patent actions to secure or dismantle market exclusivity.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
Eli Lilly is delaying its landmark drug submission to wage an administrative classification battle with the FDA that dictates years of market exclusivity.
Kailera is using US federal discovery laws as leverage to break a competitor's key oral GLP-1 patent in European jurisdictions.
Top pharmaceutical giants are using aggressive Lanham Act litigation over comparative advertising campaigns to protect their market share in court.